Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and ...

Psychedelic mushrooms, containing the active ingredient psilocybin, have shown remarkable potential in treating various ...

The government is preparing to fund the use of MDMA and psylocibin, otherwise known as ecstasy and magic mushrooms, as a ...

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Drs. Dlugos, French, O'Brien, Sourbron, and Sullivan join the Company's current SAB members, Michael P. Bogenschutz, MD, ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...